Meredith Cook Sells Shares of ANI Pharmaceuticals

Meredith Cook, Senior Vice President, General Counsel & Secretary at ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP), sold 500 shares of the company on June 12, 2026. The shares were sold at an average price of $82.03 each, totaling $41,015. This planned transaction is part of a Rule 10b5-1 trading plan.

Other Institutional Activity in ANI Pharmaceuticals

Several institutional investors have been active in ANI Pharmaceuticals recently. BlackRock, Inc. increased its holdings by 85,780 shares, ending with 2,747,492 shares valued at approximately $211.3 million. Bank of New York Mellon Corp also boosted its position by 148,357 shares to a total of 1,111,001 shares, worth about $9.78 million. Vanguard Capital Management LLC acquired 823,064 shares, now holding shares worth roughly $63.3 million. Soleus Capital Management, L.P. significantly increased its stake by 334,000 shares to 820,243 shares, valued at $63.1 million. State Street Corp raised its holdings by 44,383 shares, bringing its total to 771,587 shares worth $59.3 million.

ANI Pharmaceuticals Stock Snapshot

Shares of ANI Pharmaceuticals, Inc. traded around $82.08. The company has a market capitalization of approximately $1.86 billion and a P/E ratio of 20.89. Its forward P/E is lower at 7.64, suggesting expectations of future earnings growth. The stock's beta is 0.439, indicating lower volatility compared to the market. Over the past year, the stock has seen a low of $62.14 and a high of $99.50. The company's 50-day moving average is $79.83, while its 200-day moving average is $83.29. ANI Pharmaceuticals maintains a current ratio of 3.12 and a quick ratio of 2.43, with a debt-to-equity ratio of 112.08.

Recent Earnings

ANI Pharmaceuticals reported revenue of $923.7 million, reflecting a growth rate of 20.5%. The company's net margin stands at 9.98%, with a return on equity of 18.32%. Earnings per share (EPS) were reported at $3.91. Investors can look forward to the next earnings report on August 7, 2026.

Insider Buying and Selling at ANI Pharmaceuticals, Inc.

In addition to Meredith Cook's sale, other insiders have been active. On June 8, 2026, Thomas Haughey sold 2,000 shares at $80.88 each, also as part of a planned transaction. Earlier, on May 21, 2026, multiple insiders including Renee Tannenbaum, Thomas Haughey, Antonio Pera, and Matthew Leonard each acquired 4,357 shares, although these transactions were not planned.

Analysts Set New Price Targets

On January 16, 2026, Guggenheim maintained its "buy" rating on ANI Pharmaceuticals, setting a price target of $124. The consensus among analysts is a "strong buy" with a mean target price of $112.71, based on seven analyst opinions.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., based in Baudette, Minnesota, is a biopharmaceutical company that develops, manufactures, and markets both branded and generic pharmaceutical products. The company's offerings include injectables, softgel capsules, and Cortrophin gel, among others. It serves a variety of clients, including national wholesalers, specialty pharmacies, and healthcare providers. Led by CEO Mr. Nikhil Lalwani, ANI Pharmaceuticals employs around 970 people.

Bottom Line

Meredith Cook's recent sale of shares in ANI Pharmaceuticals is a planned move under a trading plan. The company is closely watched by investors due to its strong financial performance and active institutional interest. With a robust market cap and promising growth prospects, ANI Pharmaceuticals remains a focal point in the healthcare sector. As always, remember that insider transactions are often planned and do not necessarily reflect the current outlook of the company.